

MEDIA RELEASE • MEDIA RELEASE • MEDIA RELEASE

Alcon Announces U.S. Launch of TRYPTYR (acoltremon ophthalmic solution) 0.003%, a New Prescription Treatment Option for Millions of Dry Eye Sufferers

- TRYPTYR is a first-in-class TRPM8 receptor agonist for the treatment of the signs and symptoms of Dry Eye Disease (DED) that rapidly stimulates natural tear production as early as Day 1¹⁻³
- Many commonly used DED treatment options have limitations, including slow onset, creating a need for additional treatment options⁴⁻¹⁰
- TRYPTYR is now available to prescribe, supported by a dedicated dry eye sales team and a patient access and affordability program

Fort Worth, Texas, July 29, 2025--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. commercial availability of TRYPTYR® (acoltremon ophthalmic solution) 0.003%, the latest innovation for the treatment of the signs and symptoms of Dry Eye Disease (DED).¹ Approved by the U.S. Food and Drug Administration (FDA) in May, Eye Care Professionals (ECPs) across the U.S. can officially begin prescribing TRYPTYR to their patients, expanding their DED treatment options for the more than 30 million Americans suffering with dry eye symptoms.¹¹

"TRYPTYR is highly anticipated in the Dry Eye Disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one," said Lisa Praeger, Vice President, General Manager, U.S. Ocular Health Pharmaceutical, Alcon. "As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to Eye Care Professionals and the millions of patients who need Dry Eye Disease relief. Leveraging our deep commercial expertise and specialized sales force, we're excited to give broader access to this important new treatment option."

Many commonly used DED treatment options have limitations, including slow onset. Among surveyed dry eye patients, only 13% felt their dry eye was well managed.^{4-10*} A first-in-class TRPM8 receptor agonist (neuromodulator), TRYPTYR demonstrated statistically significant increase in natural tear production as early as Day 1.^{2,3}

"Understanding patients' Dry Eye Disease struggles allow us to make informed recommendations on how to best manage their symptoms and create an effective ongoing disease management plan," said Paul Karpecki, OD, Director of Corneal Services and the Advanced OSD Clinic in Lexington, Kentucky. "TRYPTYR represents an important innovation—its fast onset and novel mechanism provide a new option to millions of dry eye patients."

Committed to supporting ECPs with innovative products and educational resources, Alcon and its team of dedicated dry eye sales specialists have also launched an ECP campaign focusing on the speed of rapid natural tear production with TRYPTYR. The campaign features ECP tools, including videos and an interactive website along with a patient website. Additionally, Alcon recently hosted a national broadcast event for ECPs, featuring in-depth conversations surrounding this DED treatment option.

"TRYPTYR is an important milestone in the treatment of Dry Eye Disease, and I'm equally encouraged by Alcon's commitment to supporting eye care as we continue to address the signs and symptoms of Dry Eye Disease for our patients," said Preeya K. Gupta, MD, Triangle Eye Consultants in Raleigh, North Carolina. "Alcon is not only expanding the dry eye treatment options, but they are also supporting clinicians with the educational resources needed to confidently integrate new treatments like TRYPTYR into our practices."

The U.S. launch will also coincide with expansive access initiatives, including a full Field Access Management team dedicated to assisting ECPs with fulfillment, and a First Fill Free trial program for eligible TRYPTYR patients. Additionally, ongoing copay support will be offered for refills for eligible patients.

For ECPs interested in more information on TRYPTYR, visit <https://tryptyr.myalcon.com/professional/>.

INDICATIONS AND USAGE

TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).^t

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.

Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.

Adverse Reactions

In clinical trials, the most common adverse reaction was instillation site pain (50%).

Please click [here](#) for the TRYPTYR Full Prescribing Information.

About Dry Eye

Dry Eye Disease (DED) is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally.¹¹ While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender.¹² Many existing prescription options for DED are generally regarded by many Eye Care Professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability.¹³

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our

Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

References

**Based on an online survey conducted by Chronic Dry Eye from February to April 2021 among 415 responders who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (i.e., levels 3 and 4).*

1. TRYPTYR® U.S. FDA Prescribing Information. 2025.
2. Data on File for COMET-2 Phase 3 Study. Alcon 2025.
3. Data on File for COMET-3 Phase 3 Study. Alcon 2025.
4. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. *Ophthalmology*. 2007;114(1):76-79. doi: 10.1016/j.ophtha.2006.05.077.
5. Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. *Clin Ophthalmol*. 2016;10:1083-1094. doi: 10.2147/OPTH.S110557.
6. Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
7. Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra®) in the U.S. and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. *Clin Ophthalmol*. 2021;15:1041-1054. doi: 10.2147/OPTH.S296510.
8. Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. *Ophthalmol Ther*. 2019;8(3):407-420. doi: 10.1007/s40123-019-0188.
9. Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society for Cataract and Refractive Surgery Conference; April 5-6, 2024; Boston, MA.
10. Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings: living with chronic dry eye. *ChronicDryEye*. August 10, 2021. Accessed September 23, 2024. <https://chronicdryeye.net/infographic/in-america-findings>.
11. 2023 Dry Eye Products Markets Report, Market Scope, 2023.
12. The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov).
13. Improved Dry Eye Drugs for 2022 and Beyond; <https://www.aao.org/eye-health/tips-prevention/new-dry-eye-treatments-ocular-surface-disease>.

Connect with us on



Investor Relations

Daniel Cravens

Allen Trang

+ 41 589 112 110 (Geneva)

+ 1 817 615 2789 (Fort Worth)

investor.relations@alcon.com

Media Relations

Steven Smith

+ 41 589 112 111 (Geneva)

+ 1 817 551 8057 (Fort Worth)

globalmedia.relations@alcon.com